Takeda Pharmaceutical Company Limited

Ryo Mizojiri

Hiroshi Banno

Hironobu Maezaki

Moriteru Asano

Tohru Yamashita

Hideki Hirose

Koji Ono

Masahiro Ito

Toshio Tanaka

Daisuke Tomita

Tsuneo Yasuma

Hidekazu Tokuhara

Yasuyoshi Arikawa

Takaharu Hirayama

Zenichi Ikeda

Ikuo Fujimori

Yasuhiro Hirata

Yasuhiro Imaeda

Nobuki Sakauchi

Noriyuki Nii

Michiko Tawada

Nobuo Cho

Douglas Robert Cary

Akinori Toita

Hironori Kokubo

Jun Fujimoto

Takuya Fujimoto

Nao Morishita

Takeshi Yamasaki

Makoto Kamata

Nobuyuki Takakura

Masaki Ogino

Masataka Murakami

Shizuo Kasai

Tomoya Yukawa

Nobuyuki Matsunaga

Asato Kina

Kazuko Yonemori

Krista E Gipson

Sachie Morimoto

Yuichiro Amano

Kyoko Toyofuku

Mayumi Imai

Shuntarou Tsuchiya

Takashi Nakahata

Shuntaro Tsuchiya

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I):

Nitrogen containing heterocycles as CDK12 inhibitors

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic compound

Provided is a bicyclic compound having an acetyl-CoA carboxylase inhibitory action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has an acetyl-CoA carboxylase inhibitory action, is useful for the prophylaxis or treatment of cancer, inflammatory diseases and the like, and has superior efficacy.

Bicyclic compound

The present invention relates to a compound which may be useful as an agent for the prophylaxis or treatment of cancer, hepatitis, hepatic fibrosis, fatty liver and the like.

Monocyclic compound

Provided is a compound represented by the following formula (1) or a salt thereof, which has an SSTR5 antagonistic action: wherein each symbol has the same definition as in the specification. 

Spiro azetidine isoxazole derivatives and their use as SSTR antagonists

The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

The present invention provides to a compound having an ACC inhibitory action, which is useful as an agent for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification.

Growing community of inventors

Kanagawa, Japan

Ryo Mizojiri